Recent Security Class Actions

UroGen Pharma Ltd. Ordinary Shares (NASDAQ: URGN)

53 Days left to seek lead plaintiff status.

Company Name:UroGen Pharma Ltd. Ordinary Shares
Stock Symbol:NASDAQ: URGN
Class Period Start:07/27/2023
Class Period End (inclusive):05/15/2025
Filing Deadline:07/28/2025

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA’s warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

UroGen Pharma Ltd. Ordinary Shares (NASDAQ: URGN) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.